On Lactococcus lactis UL719 competitivity and nisin (Nisaplin®) capacity to inhibit Clostridium difficile in a model of human colon by Christophe Le Lay et al.
ORIGINAL RESEARCH
published: 25 September 2015
doi: 10.3389/fmicb.2015.01020
Edited by:
Yuji Morita,
Aichi Gakuin University, Japan
Reviewed by:
Michael Gänzle,
University of Alberta, Canada
Maria De Los Angeles Serradell,
Universidad Nacional de La Plata,
Argentina
Carolina Ibarguren,
Consejo Nacional de Investigaciones
Científicas y Técnicas, Argentina
*Correspondence:
Ismail Fliss,
STELA Dairy Research Center,
Nutrition and Functional Foods
Institute, Université Laval,
G1V 0A6 Québec, QC, Canada
ismail.fliss@fsaa.ulaval.ca
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 07 July 2015
Accepted: 08 September 2015
Published: 25 September 2015
Citation:
Le Lay C, Fernandez B, Hammami R,
Ouellette M and Fliss I (2015) On
Lactococcus lactis UL719
competitivity and nisin (Nisaplin R©)
capacity to inhibit Clostridium difficile
in a model of human colon.
Front. Microbiol. 6:1020.
doi: 10.3389/fmicb.2015.01020
On Lactococcus lactis UL719
competitivity and nisin (Nisaplin©R )
capacity to inhibit Clostridium
difficile in a model of human colon
Christophe Le Lay1,2,3, Benoit Fernandez1, Riadh Hammami1, Marc Ouellette2,3 and
Ismail Fliss1*
1 STELA Dairy Research Center, Nutrition and Functional Foods Institute, Université Laval, Québec, QC, Canada, 2 Centre de
Recherche en Infectiologie de l’Université Laval, Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU
de Québec, Québec, QC, Canada, 3 Département de Microbiologie-Infectiologie et d’Immunologie, Faculté de Médecine,
Université Laval, Québec, QC, Canada
Clostridium difficile is the most frequently identified enteric pathogen in patients with
nosocomially acquired, antibiotic-associated diarrhea and pseudomembranous colitis.
Although metronidazole and vancomycin were effective, an increasing number of
treatment failures and recurrence of C. difficile infection are being reported. Use of
probiotics, particularly metabolically active lactic acid bacteria, was recently proposed
as an alternative for the medical community. The aim of this study was to assess
a probiotic candidate, nisin Z-producer Lactococcus lactis UL719, competitivity and
nisin (Nisaplin©R ) capacity to inhibit C. difficile in a model of human colon. Bacterial
populations was enumerated by qPCR coupled to PMA treatment. L. lactis UL719 was
able to survive and proliferate under simulated human colon, did not alter microbiota
composition, but failed to inhibit C. difficile. While a single dose of 19 μmol/L (5×
the MIC) was not sufficient to inhibit C. difficile, nisin at 76 μmol/L (20×the MIC) was
effective at killing the pathogen. Nisin (at 76 μmol/L) caused some temporary changes
in the microbiota with Gram-positive bacteria being the mostly affected. These results
highlight the capacity of L. lactis UL719 to survive under simulated human colon and
the efficacy of nisin as an alternative in the treatment of C. difficile infections.
Keywords: Clostridium difficile, probiotic, Lactococcus lactis UL719, bacteriocin, nisin, colon model
Introduction
Clostridium diﬃcile is a Gram-positive anaerobic sporulating pathogen causing intestinal
infections following disturbance of the human and animal gut microbiota, usually subsequent
to an antibiotic therapy. C. diﬃcile is now thought to be responsible for a wide range of
diseases including acute diarrhea and pseudomembranous colitis, and could lead to colonic
perforation and death if untreated (Borriello et al., 1990). Although metronidazole and
vancomycin are well-established treatments for C. diﬃcile infections (CDI) (Surowiec et al.,
2006; Kelly and LaMont, 2008), an increasing number of treatment failures with these
antibiotics and recurrence of C. diﬃcile infection are being reported, reviewed in Vardakas
et al. (2012). Vancomycin is also losing its attractiveness for CDI treatment with emergence
of vancomycin-resistant enterococci and dissemination of antibiotic-resistance determinants
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within the hospital environment (Lagrotteria et al., 2006). The
emergence of C. diﬃcile isolates with multiple-drug resistance is
rarely explicitly mentioned (Peláez et al., 2002; Mutlu et al., 2007),
but constitutes further a serious public health threat that urges the
need of novel antimicrobial treatments.
Previously, a large number of clinical trials highlighted the
positive role of probiotics in the treatment of diarrhea by either
shortening its duration and/or preventing its complications in
infants and young children, reviewed in Guandalini (2011). In
instance, a yogurt containing a combination of Lactobacillus
rhamnosus GG, L. acidophilus La-5, and Biﬁdobacterium lactis
Bb12 was shown to be an eﬀective method for reducing the
incidence of antibiotic-associated diarrhea in children (Fox
et al., 2015). Moreover, diﬀerent probiotics (Saccharomyces
boulardii, L. casei DN114001, a mixture of L. acidophilus
and B. biﬁdum, and a mixture of L. acidophilus, L. casei
and L. rhamnosus) signiﬁcantly improved CDI prevention,
reviewed in McFarland (2015). Although several meta-analyses
pointed the positive eﬀect of probiotics, their role in the
prevention of CDI remains unclear. The health-promoting
properties of probiotics are numerous and their eﬀects on
host include competition with pathogens for adhesion sites and
nutrients, stimulation of immunity/immunomodulation, and
production of inhibitory substances such as bacteriocins (Fliss
et al., 2011). Bacteriocins have been suggested as promising
alternative to conventional antibiotics (Rea et al., 2007, 2010),
and their production is being considered as a probiotic trait
although not clearly demonstrated in vivo (Dobson et al.,
2012). While several bacteriocins including nisin (Le Blay
et al., 2007; Le Lay et al., under revision), Microbisporicin
(Castiglione et al., 2008), Lacticin 3147 (Rea et al., 2007) and
thuricin CD (Rea et al., 2010) were shown eﬀective against
C. diﬃcile, to date only nisin is approved by the American
Food and Drug Administration, the World Health Organization,
and the European Union as natural food additive (Delves-
Broughton, 1990). Nisin displays high antibacterial activity
against multi-resistant Streptococcus pneumoniae, methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococcus faecium, E. faecalis, and C. diﬃcile (Severina et al.,
1998; Le Blay et al., 2007).
Previously, we have observed that potential probiotic
Lactococcus lactis UL719, a nisin Z producer, was able to
survive through the gastrointestinal tract (unpublished data).
The strain L. lactis UL719 was able to grow and inhibit
Listeria in a medium simulating the nutrient composition of
the human colon (Fernandez et al., 2013). The aim of this
study was to evaluate the capacity of L. lactis UL719 and
nisin (Nisaplin R©) to inhibit C. diﬃcile in a model of the
colon mimicking physiological and microbiological conditions
of the large intestine. In addition, impact of both strain and
its bacteriocin on the gut microbiota composition were also
investigated.
Materials and Methods
Bacterial Strains and Growth Conditions
Lactococcus lactis sp. lactis biovar. diacetylactis UL719, a nisin
Z-producer, was isolated from raw milk cheese (Ali et al.,
1995; Meghrous et al., 1997). C. diﬃcile ATCC43255 was
purchased from ATCC (American Type Culture Collection,
Manassas, VA, USA). L. lactis UL719 was reactivated in De
Man Rogosa Sharpe (MRS) broth (Difco Laboratories, Sparks,
MD, USA) and cultivated for 24 h at 30◦C. C. diﬃcile
was reactivated in Brain Heart Infusion (BHI) broth (Difco
laboratories, Sparks, MD, USA) supplemented with 0.05%
L-cysteine-HCl (Sigma chemicals). C. diﬃcile culture was
cultivated in an anaerobic chamber (Forma scientiﬁc anaerobic
system Model 1025; Forma Scientiﬁc, Marietta, OH, USA) at
37◦C for 24 h. Escherichia coli ATCC25922 and E. faecalis
ATCC27275 were grown aerobically at 37◦C for 24 h in BHI
and TSBYE, respectively. B. adolescentisATCC15703, Bacteroides
thetaiotaomicron ATCC29741, Blautia coccoides ATCC29236,
and C. leptum ATCC29065 were, respectively, grown in MRS
broth (0.05% L-cysteine-HCl), BHI (0.05% L-cysteine-HCl) and
a modiﬁed chopped meat medium with maltose (ATCCmedium
2751) under anaerobic conditions at 37◦C. All bacterial strains
were maintained in 20% glycerol at −80◦C. Prior to each
experiment, each bacterial strain was subcultured at least three
times (inoculation at 1%, v/v) at 24 h intervals.
FIGURE 1 | Time schedule of continuous intestinal fermentation during the different treatment periods. BC, bead colonization. Lactococcus lactis UL719
was added at final concentration of 109 CFU/mL in the reactor. Clostridium difficile ATCC43255 was added at a final concentration of 5 × 106 CFU/mL.
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TABLE 1 | Primers used for the detection of different bacterial groups in inoculum or fermentation samples by real-time qPCR analysis.
Target organisms Gene Sequence 5′–3′ Reference
All bacteria 16S f: TCCTACGGGAGGCAGCAGT Hopkins et al., 2005
r: GGACTACCAGGGTATCTAATCCTGTT
Ruminococcaceae (Clostridium leptum) 16S f: GCACAAGCAGTGGAGT Kanno et al., 2009
r: CTTCCTCCGTTTTGTCAA
Lachnospiraceae (Blautia coccoides) 16S f: AAATCACGGTACCTGACTAA Matsuki et al., 2002
r: CTTTGAGTTCATTCTTGCGAA
Bifidobacteria sp. 16S f: TCGCGTC(C/T)GGTGTGAAAG Rinttilä et al., 2004
r: CCACATCCAGC(A/G)TCCAC
Enterobacteriaceace sp. 16S f: CATGCCGCGTGTATGAAGAA Huijsdens et al., 2002
r: CGGGTAACGTCAATGAGCAAA
Bacteroidetes 16S f: GGTGTCGGCTTAAGTGCCAT Rinttilä et al., 2004
r: CGGA(C/T)GTAAGGGCCGTGC
Lactobacillaceae/Leuconostocaceae group 16S f: AGCAGTAGGGAATCTTCCA Rinttilä et al., 2004
r: CGCCACTGGTGTTCYTCCATATA
C. difficile tcdA f: CTCCTGGACCACTTAAACTTATTGTG This study
r: GCTACCGCAGAAAACTCTATGTTTT
Lactococcus lactis UL719 nisI f: CTGAAGTACGTGTGTTTGATTCAGTTAG Trmcˇiac´ et al., 2011
r: TCGCCATAATCCCATTCCGTC
TABLE 2 | Bacterial cell counts in the fecal inoculum and during the
fermentation at the end of the stabilization period of the continuous
culture measured by qPCR.
Bacterial
population
Fecesa Inoculumb End of
stabilizationc
CFSd
qPCR qPCR
Total bacteria 10.6–11.6 10.84 ± 0.04 11.11 ± 0.17 8.9–10.2
Lachnospiraceae
group
9.9–11.1 9.46 ± 0.02 8.14 ± 0.05 7–9.5
Ruminococcaceae
group
10.52 ± 0.02 9.43 ± 0.01
Bacteroidetes 9.2–10.3 10.85 ± 0.02 10.52 ± 0.08 6.8–10.1
Bifidobacterium sp. 7.2–10.2 10.16 ± 0.15 6.14 ± 0.08 6.0–9.0
Enterobacteriaceae
sp.
8.0–9.8 7.24 ± 0.53 8.73 ± 0.01 7.3–9.2
Lactobacillaceae/
Leuconostocaceae
group
8.6–9.5 6.98 ± 0.19 3.82 ± 0.14 <6.0–8.3
aFecal populations (log10 CFU/g) of healthy adults reported in various studies and
measured by FISH (Franks et al., 1998; Harmsen et al., 1999).
bBacterial concentrations (log10 CFU/g of feces).
cBacterial concentrations (log10 CFU/mL).
dBacterial concentrations (log10 CFU/mL) reported for in vitro continuous
fermentation samples (CFS) and measured by FISH (Brück et al., 2002; Probert
and Gibson, 2004; Cleusix et al., 2008; Le Blay et al., 2012).
Development of Large Intestine Fermentation
Model
Feces Collection and Immobilization in Gel Beads
A fresh fecal sample was obtained from one 27 years old healthy
donor who had not taken antibiotics for the previous 3 months.
The collected fecal sample was used for immobilization following
procedure described by Le Blay et al. (2012). The entire process
was completed aseptically under anaerobic conditions within 1 h
after sample collection.
Nutritive Medium
The culture medium used for colonic fermentation was the same
as described by Macfarlane et al. (1998) with some modiﬁcations.
Brieﬂy, 0.5 mL of a vitamin solution (mg/L: pyridoxine–HCl
20; p-aminobenzoic acid 10; nicotinic acid 10; biotin 4; folic
acid 4; vitamin B12 1; thiamine 8; riboﬂavin 10; menadione 2;
vitamin K1 0.005; pantothenate 20) described by Gibson and
Wang (1994) was added to each liter of the culture medium. The
vitamin solution was sterilized by ﬁltration (0.2 μm, VWR) and
added to the autoclaved medium (15 min, 121◦C) after cooling at
room temperature.
Experimental Setup and Sampling
The colonic fermentation was based on the model described by
Cinquin et al. (2004). A single-stage reactor (Bioﬂo III, New
Brunswick Scientiﬁc Inc., Edison, NJ, USA) with 1 L working
volume containing 30% (v/v) of freshly prepared beads was
used to mimic the microbial ecosystem of adult distal colon.
The colonization of beads with fecal microbiota was carried
out during 2 days, and the nutritive medium was aseptically
replaced by fresh culture medium every 12 h. pH (6.2) and
anaerobic and temperature (37◦C) conditions were maintained
during the whole fermentation by addition of 5 M NaOH and a
continuous ﬂow of pure CO2 in the headspace. The continuous
fermentation was carried out in the same reactor connected to
a stirred feedstock vessel containing the sterile culture medium
at 4◦C under a CO2 atmosphere and to an eﬄuent-receiving
vessel. Feed ﬂow rate was adjusted to 83.3 mL/h to mimic
a mean retention time of 12 h encountered in adult distal
colon.
The fermentation process was carried out for a total of 82 days
and microbiota was stabilized 2 weeks before challenging tests.
First, a cell suspension of L. lactis UL719 (at ﬁnal concentration
109 CFU/mL in the reactor) was added twice to the reactor
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TABLE 3 | Impact of L. lactis UL719 (109 CFU/mL) and/or C. difficile ATCC43255 (5 × 106 CFU/mL) addition on the microbiota.
Bacterial population L. lactis UL719 C. difficile L. lactis UL719 + C. difficile
0 8 h 0 8 h 0 8 h
Total bacteria 10.87 ± 0.13 10.80 ± 0.19 10.80 ± 0.08 10.71 ± 0.04 10.40 ± 0.31 10.66 ± 0.19
Lachnospiraceae group 8.05 ± 0.25 8.04 ± 0.28 8.06 ± 0.09 8.01 ± 0.05 7.42 ± 0.24 7.76 ± 0.23
Ruminococcaceae group 9.36 ± 0.10 9.32 ± 0.17 9.29 ± 0.03 9.25 ± 0.02 8.93 ± 0.21 9.23 ± 0.09
Bacteroidetes 10.51 ± 0.04 10.32 ± 0.11 10.31 ± 0.16 10.06 ± 0.13 9.82 ± 0.60 10.18 ± 0.33
Bifidobacteria 6.35 ± 0.17 6.13 ± 0.79 5.26 ± 0.84 5.18 ± 0.81 5.56 ± 0.69 5.61 ± 0.07
Enterobacteriaceae 8.95 ± 0.10 8.81 ± 0.22 9.49 ± 0.08 9.28 ± 0.04 9.20 ± 0.31 9.23 ± 0.25
Lactobacillaceae/Leuconostocaceae group 3.69 ± 0.15 3.57 ± 0.47 5.75 ± 0.44 5.46 ± 0.36 5.43 ± 0.28 5.59 ± 0.32
Data are mean ± standard deviation of two biological replicates and three technical replicates. Values are not significantly different by the student’s test (P < 0.05).
(day 17 and 22) (Figure 1). Then, nisin A (Nisaplin R© , Danisco,
Copenhagen, Denmark) was added to the reactor at 5× (at day
27 and 32) and 20× (at day 37 and 42) the MIC (3.8 μmol/L
vs. C. diﬃcile) to measure the impact of high doses of nisin on
the intestinal ﬂora. Next, challenges with C. diﬃcile ATCC43255
(at a ﬁnal concentration of 5 × 106 CFU/mL in the reactor)
in absence (day 47 and 52) or in presence of L. lactis (added
at a ﬁnal concentration of 109 CFU/mL in the reactor; day 57
and 62) or in presence of diﬀerent concentrations of nisin A
[5× (day 67 and 72) or 20× (day 77 and 82) the MIC] were
performed. Samples were collected for bacterial enumeration by
qPCR. After each addition, samples were hourly taken during ﬁrst
4 and at 8 h.
Microbiota Composition Analysis using q-PCR
Coupled to PMA Treatment
Standard curve for the qPCR quantiﬁcation was done using
the following strains: E. coli ATCC 25922, B. adolescentis
ATCC15703, B. thetaiotaomicron ATCC29741, C. leptum
ATCC29065, B. coccoides ATCC29236, and E. faecalis
ATCC27275. Samples were collected from the reactor
and treated with propidium monoazide (Biotium, Inc.,
Hayward, CA, USA) prior enumeration of viable bacteria,
as described in Fernandez et al. (2015). The DNA from fecal
and fermentation samples were then extracted following
the protocol of Ahlroos and Tynkkynen (2009) using the
Wizard R©genomic DNA Puriﬁcation Kit (Promega, Madison,
WI, USA) with some modiﬁcations (Fernandez et al., 2015).
Real-time PCR was carried out on an ABI 7500 real-time
PCR system (Applied biosystem, Streetsville, ON, Canada)
with the iTaqTM Universal SYBR R©Green supermix (Biorad,
Oakville, ON, Canada) in 96-well plates following method
described in Fernandez et al. (2015). Primers used in this
study are summarized in Table 1. Each sample was done in
triplicate.
Analyses of Metabolites
Short-chain fatty acids (SCFA: acetate, propionate, butyrate,
and valerate) and isoacids (isobutyrate and isovalerate) were
determined by high-performance liquid chromatography
(HPLC) analysis (Waters, Milford, MA, USA) equipped
with an Ion 300 column (Transgenomic, San Jose, CA,
USA), a diﬀerential refractometer (Model R410, Waters) as
previously described by Cinquin et al. (2004). The analysis
was performed at a ﬂow rate of 0.4 mL/min at 37◦C, with
an injection volume of 100 μL. Each analysis was done in
duplicate. The mean metabolite concentrations were expressed
in mmol/L.
Statistical Analysis
Data are presented as means ± SD. Cell counts values were
log10-transformed and analyzed for repeated measures using
the PROC MIXED procedure of SAS v9.2 statistical package
(SAS Institute Inc., Cary, NC, USA). The statistical diﬀerences
in metabolites contents between treatments were evaluated
using a one-way ANOVA t-test. The level of signiﬁcance was
P ≤ 0.05.
Results
Microbiota Composition during Stabilization
Period
Bacterial populations enumerated by qPCR coupled to PMA
treatment in the fecal inoculum and eﬄuent samples at
the end of stabilization period are summarized in Table 2.
The fecal inoculum presented a total bacterial cell counts of
11.84 ± 0.04 log10 CFU/g, which was dominated by Bacteroidetes
(10.85 ± 0.02 log10 CFU/g), clostridia (10.55 ± 0.02 log10
CFU/g), and biﬁdobacteria (10.16 ± 0.15 log10 CFU/g).
At the end of the stabilization period (16 days) under
simulated colon conditions, the microbiota population
reached a pseudo steady state in which a slight change was
observed in the microbial balance, compared to the initial
fecal inoculum. The microbiota decreased by −0.7 log10
CFU/mL at this stage and was dominated by Bacteroidetes group
with 10.52 ± 0.08 log10 CFU/mL. While Enterobacteriaceae
group increased by 1.49 log10 and reached 8.73 ± 0.01 log10
CFU/mL, biﬁdobacteria, and Lactobacillaceae/Leuconostocaceae
group populations dropped to 6.14 ± 0.08 and 3.82 ± 0.14
log10 CFU/mL, respectively. Nevertheless, the obtained
results are in accordance to those previously reported for
colonic fermentation models (Brück et al., 2002; Probert
and Gibson, 2004; Cleusix et al., 2008; Le Blay et al.,
2012).
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Lactococcus lactis UL719 Alone or in Presence
of C. difficile ATCC43255 have no Perturbing
Impact on Intestinal Microbiota under
Simulated Colonic Conditions
After the stabilization period, L. lactis UL719, C. diﬃcile
ATCC43255, and their combination were successively added to
the bioreactor and themicrobiota populations weremonitored by
qPCR (Table 3). Interestingly, the addition of L. lactis UL719 at
1 × 109 CFU/mL to the bioreactor, did not induce any signiﬁcant
change neither in the intestinal microbiota composition nor
in metabolites production (Table 4). Since the last addition
of L. lactis UL719 to the reactor, the strain was detected at
about 0.1 − 1 × 109 CFU/mL during the remaining 20 days of
fermentation (Figure 2). While the infection of the bioreactor
with 5 × 106 CFU/mL of C. diﬃcile did not aﬀect the microbiota
composition, a slight but signiﬁcant decrease (p < 0.05) of
acetate and butyrate was detected (from 76.24 to 72.59 mmol/L
and from 32.13 to 29.54 mmol/L, respectively) (Table 4).
Simultaneous addition of C. diﬃcile and L. lactis UL719 had no
impact on the microbiota cell counts but a signiﬁcant decrease
(p < 0.05) of butyrate (from 32.13 to 28.40 mmol/L). Under
these conditions, L. lactis has no inhibitory eﬀect on C. diﬃcile
(Figure 3).
A Nisin Concentration of 20× the MIC is
Required to Effective Inhibition of C. difficile
ATCC43255 in a Model of Human Colon
The microbiota was challenged by 5× and 20× the MIC
vs. C. diﬃcile ATCC43255. Nisin at 5× the MIC did not
alter the microbiota which remained stable (data not shown)
although minor variations in the metabolite production proﬁle
(Table 4). At a nisin concentration of 20× the MIC, total
microbiota signiﬁcantly decreased by 0.7 log10 (p < 0.008), as
shown in Figure 4. Gram-positive bacteria were aﬀected by
this higher amount of nisin, with Ruminococcaceae group being
the mostly altered (−3.7 log10) after 24 h. In a lesser extent,
a reduction of 1.5 log10, 1.3 log10, and 1 log10 were recorded
for Lachnospiraceae group, Lactobacillaceae/Leuconostocaceae
FIGURE 2 | Survival of L. lactis UL719 after its last addition (day 62) in a
human colon model. L. lactis UL719 (circle); theoretical washout (square).
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FIGURE 3 | Inhibitory activity of nisin at 5× and 20× the MIC
(3.8 µmol/L) and L. lactis UL719 (109 CFU/mL) against C. difficile
ATCC43255 in a human colon model. C. difficile alone (black diamond);
C. difficile plus nisin 5× (white triangle); C. difficile plus nisin 20× (cross);
C. difficile plus L. lactis UL719 (white circle); theoretical washout (white
square).
group and biﬁdobacteria, respectively. After 24 h of nisin
administration, all bacterial populations recovered their initial
counts except Ruminococcaceae group which dropped to its
minimum counts. While acetate and butyrate signiﬁcantly
decreased (p < 0.05) from 76.24 and 32.13 mmol/L to 69.12
and 26.29 mmol/L, propionate production increased by 13%
(Table 4). Besides, a nisin concentration of 5× did not inhibit
C. diﬃcile, which counts remained close to control (C. diﬃcile
alone) (Figure 3). Conversely, nisin at 20× was eﬀective at
inhibiting C. diﬃcile with a signiﬁcant reduction (p < 0.001) of
FIGURE 4 | Impact of nisin addition at 76 µmol/L (20× the MIC vs.
C. difficile ATCC43255) on microbiota population enumerated by
qPCR. Total bacteria (white diamond); Lachnospiraceae group. (white
square); Ruminococcaceae group. (white triangle); Bacteroidetes (cross);
Bifidobacteria (black triangle); Enterobacteriaceae (white circle);
Lactobacillaceae/Leuconostocaceae group. (black square); Values with
asterisk are significantly different (P < 0.05).
2.3 log10 at 1 h that lasted for 8 h (Figure 3). C. diﬃcile was not
detected after 24 h in this model (data not shown).
Discussion
Previously, we have demonstrated the nisin eﬃcacy against
several clinical isolates of C. diﬃcile vegetative cells and spores
(Le Lay et al., under revision). In addition, we have observed that
L. lactis UL719, a nisin Z producer, was able to survive these GIT
stressful conditions, to keep ability to produce its bacteriocin,
and to reach the colon in large enough numbers (>108 CFU)
to comply with the recommended daily dose of 108–109 cells
delivery to exert a beneﬁcial eﬀect on the host (unpublished
data). The aim of this study was to assess L. lactis UL719
competitivity and nisin capacity to inhibit C. diﬃcileATCC43255
in a model of human colon. In this study, L. lactis UL719
at 109 CFU/mL did not induce any signiﬁcant change neither
in the intestinal microbiota composition nor in metabolites
production. The strain was monitored by quantiﬁcation of nisI
gene by PMA-qPCR, and found able to survive and proliferate
up to 108 CFU/mL in our colonic model during the 82 days
of fermentation (Figure 2). Unlikely, L. lactis DPC6520 was
shown more susceptible to GIT conditions, which cell counts
were reduced by 10 000-fold 24 h after its inoculation into
a colon model (Dobson et al., 2011). Likewise, a 19 μmol/L
concentration of nisin (corresponding to 5× the MIC vs.
C. diﬃcile ATCC43255) did not alter microbiota levels. At
a higher concentration of 76 μmol/L (20×), Gram-positive
bacteria were aﬀected and Ruminococcaceae group was the
mostly altered (−3.7 log10), while increase in Gram-negative
population (Bacteroidetes and Enterobacteriaceae) were observed.
Nevertheless, the initial bacterial balance was quickly restored
within 24 h after the addition of 20× nisin. Previously, we
have shown in vitro the sensitivity of colonic Gram-positive
bacteria such as B. biﬁdum DSM 20456, L. fermentum ETHZ,
C. clostridioforme DSM933, Eubacterium biforme DSM3989 to
nisin (Le Blay et al., 2007). Recently, Rea et al. (2011) reported
that lacticin 3147 induce similar variations in microbiota
composition, with a decrease in Firmicutes abundance in favor of
Proteobacteria. Broad-spectrum antibiotics like vancomycin and
metronidazole seems to induce also decrease of Firmicutes and an
increase in Enterobacteriaceae and Proteobacteria (Antonopoulos
et al., 2009; Rea et al., 2011). More recently, thuricin CD, a
narrow spectrum bacteriocin produced by Bacillus thuringiensis,
was used in the distal colon model and had no signiﬁcant impact
on the composition of the microbiota (Rea et al., 2011).
Although its capacity to survive colonic conditions, L. lactis
UL719 had no signiﬁcant eﬀect on C. diﬃcile. Similar
results were previously reported with L. lactis DPC6520
(a lacticin 3147 producer) and L. lactis DPC6519 (lacticin
non-producer) in an ex vivo human colonic model (Dobson
et al., 2011). Although L. lactis UL719 is able to produce
nisin in a Macfarlane medium simulating the nutrient
composition of the colon (Fernandez et al., 2013), the lack
of eﬀectiveness observed here is likely due to no or a low
production of nisin, not suﬃcient to inhibit C. diﬃcile.
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Conversely, L. salivarius UCC118 has demonstrated its capacity
to produce the Abp118 bacteriocin in vivo and to protect
mice against infection with the invasive foodborne pathogen
Listeria monocytogenes. This protection was related to bacteriocin
production, and mutant of L. salivarius UCC118 lacking the
bacteriocin gene failed to protect mice against infection (Corr
et al., 2007). Some similar results were obtained with human
L. lactis and Pediococcus acidilactici nisin- and pediocin-
producing strains that were able to reduce vancomycin-resistant
enterococci intestinal colonization in a mouse model (Millette
et al., 2008).
Although L. lactis UL719 had no signiﬁcant eﬀect on
C. diﬃcile in this model of human colon, addition of nisin (in
Nisaplin R©form) at 76 μmol/L induced a signiﬁcant reduction of
C. diﬃcile. The observed eﬃcacy of Nisaplin R©against C. diﬃcile
could be due to a synergy between nisin and salt present
in the commercial product. At lower concentration of nisin
(19 μmol/L), we did not show any signiﬁcant eﬀect on C. diﬃcile,
its rapid adsorption on the surface of the colonic microbiota or
its inactivation due to enzymatic activities (proteolysis mainly)
could explain this lack of activity (Dobson et al., 2011). Rea et al.
(2011) have reported on the eﬀectiveness of other bacteriocins
such as lacticin 3147 and thuricin CD against C. diﬃcile
in a distal colon model. Lacticin 3147 (270 μmol/L) and
thuricin CD (90 μmol/L) aﬀected the viability of C. diﬃcile
(106 CFU/mL) with a loss of detection after 12 h and three
log10 reduction after 24 h, respectively (Rea et al., 2011). After
respective addition of lacticin 3147 (270 μmol/L) and thuricin
CD (90 μmol/L), authors have shown a CFU reduction of 4
log10 and 1.2 log10, but lacticin at 90 μmol/L had no signiﬁcant
eﬀect on the C. diﬃcile viability (Rea et al., 2011). In this
study, nisin was as eﬀective as lacticin 3147 and more eﬃcient
than thuricin CD with a CFU reduction of 3.23 log10 with
nisin (76 μmol/L) compared to initial time. Besides, three
times addition of vancomycin (90 μmol/L) or metronidazole
(90 μmol/L) is required to induce a signiﬁcant eﬀect on
C. diﬃcile after 24 h (Rea et al., 2011). A single dose of nisin
(76 μmol/L) was as eﬀective as antibiotics traditionally used to
treat CDIs.
With increase of failures and recurrences in the treatment
of CDIs, development of alternative treatments has become
necessary. In recent years, use of probiotic bacteria producing
antimicrobial molecules (such as bacteriocins) constitute a
promising alternative for prevention and treatment of C. diﬃcile
related diseases. In the study, we have shown that nisin-producer
L. lactis UL719 was able to survive and proliferate in the
human colon model. Although L. lactis UL719 failed to inhibit
C. diﬃcile in this model, L. lactis UL 719 had not aﬀected
the microbiota. Others studies aiming to increase competitivity
and nisin production will be necessary and could include the
addition of prebiotics or carbohydrate which stimulate nisin
production. Nisin (Nisaplin R©) causes some temporary changes in
the microbiota but is eﬀective at killing C. diﬃcile in the human
colon model.
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